Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression - Takeaways - MDSpire

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

  • By

  • Diming Wang

  • Tangbin Liu

  • Jian Zhao

  • Bowen Ding

  • Yongliang Niu

  • June 17, 2026

  • 0 min

Share

  • 1

    Two patients with stage III EGFR-mutant NSCLC and high PD-L1 levels achieved complete pathological response after neoadjuvant chemoimmunotherapy.

  • 2

    Case 1 involved a 60-year-old male with an EGFR exon 19 deletion who received pemetrexed, carboplatin, and pembrolizumab.

  • 3

    Case 2 involved a 52-year-old female with an EGFR exon 21 mutation who showed primary resistance to afatinib before receiving a different regimen.

  • 4

    Both patients remained disease-free after 16 and 22 months of follow-up, suggesting potential efficacy of this treatment strategy.

  • 5

    Further validation through large-scale clinical trials is necessary to establish the role of neoadjuvant chemoimmunotherapy in this patient population.

Original Source(s)

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

  • by Diming Wang, Tangbin Liu, Jian Zhao, Bowen Ding, Yongliang Niu

  • June 17, 2026

Related Content

Multimodal echocardiographic techniques in the diagnosis of cardiac tumors: applications and recent advances

Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring

Access to Specialty Cancer Care and Plan Disenrollment Among Medicare Beneficiaries